Research Article

Characterization of Diabetic Neuropathy in the Zucker Diabetic Sprague-Dawley Rat: A New Animal Model for Type 2 Diabetes

Eric P. Davidson, 1 Lawrence J. Coppey, 1 Amey Holmes, 2 Sergey Lupachyk, 1 Brian L. Dake, 1 Christine L. Oltman, 2 Richard G. Peterson, 3 and Mark A. Yorek1,2,4,5

1 Department of Internal Medicine, The University of Iowa, Iowa City, IA 52242, USA
2 Department of Veterans Affairs Iowa City Health Care System, Iowa City, IA 52246, USA
3 PreClinOmics Inc., Indianapolis, IN 46268, USA
4 Iowa City Veterans Administration Center for the Prevention and Treatment of Visual Loss, Iowa City, IA 52246, USA
5 Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA 52242, USA

Correspondence should be addressed to Mark A. Yorek; mark-yorek@uiowa.edu

Received 23 July 2014; Accepted 9 September 2014; Published 13 October 2014

Academic Editor: Norman Cameron

Copyright © 2014 Eric P. Davidson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recently a new rat model for type 2 diabetes the Zucker diabetic Sprague-Dawley (ZDSD/Pco) was created. In this study we sought to characterize the development of diabetic neuropathy in ZDSD rats using age-matched Sprague-Dawley rats as a control. Rats were examined at 34 weeks of age 12 weeks after the onset of hyperglycemia in ZDSD rats. At this time ZDSD rats were severely insulin resistant with slowing of both motor and sensory nerve conduction velocities. ZDSD rats also had fatty livers, elevated serum free fatty acids, triglycerides, and cholesterol, and elevated sciatic nerve nitrotyrosine levels. The corneas of ZDSD rats exhibited a decrease in subbasal epithelial corneal nerves and sensitivity. ZDSD rats were hypoalgesic but intraepidermal nerve fibers in the skin of the hindpaw were normal compared to Sprague-Dawley rats. However, the number of Langerhans cells was decreased. Vascular reactivity of epineurial arterioles, blood vessels that provide circulation to the sciatic nerve, to acetylcholine and calcitonin gene-related peptide was impaired in ZDSD rats. These data indicate that ZDSD rats develop many of the neural complications associated with type 2 diabetes and are a good animal model for preclinical investigations of drug development for diabetic neuropathy.

1. Introduction

Animal models have been widely used for the study of the etiology of diabetic complications. One of the models that have been used for the study of type 2 diabetes has been the Zucker diabetic fatty (ZDF) rat [1–4]. My laboratory has shown that diabetic neuropathy develops with the onset of hyperglycemia in ZDF rats; slowing of motor nerve conduction velocity is preceded by impaired vascular relaxation of epineurial arterioles of the sciatic nerve [5, 6]. We have also demonstrated that diabetic vascular and neural complications in ZDF rats have a complex etiology and are difficult to reverse [6–8]. However, one concern for the applicability of the ZDF rats for the study of diabetic complications and translation to humans is the recessive homozygous mutation in the leptin receptor (fa) that causes loss of function and induces severe hyperphagia [9, 10]. Leptin has been shown to have an array of effects that may influence development of the metabolic syndrome [11–15]. Thus, loss of leptin signaling in the ZDF rat makes it a less than ideal model for complications of type 2 diabetes in humans who generally do not have a leptin receptor deficit. These concerns have led to the creation of the Zucker diabetic Sprague-Dawley (ZDSD) rat [9, 10]. The ZDSD rat was developed by cross-breeding the Charles River Laboratory diet-induced obese rats (Sprague-Dawley-derived) with lean ZDF+/– rats. Selective inbreeding produced animals with a predisposition to obesity and a propensity to develop overt diabetes between 15 and 21 weeks of age with nutritional intervention [9]. Importantly, the ZDSD rats have an intact leptin signaling pathway and more modest accumulation of body fat in comparison to the ZDF rats [9]. The objective
of this study was to characterize endpoints associated with diabetic neuropathy in ZDSD rats compared to age matched Sprague-Dawley rats.

2. Materials and Methods

Unless stated otherwise all chemicals used in these studies were obtained from Sigma Chemical Co. (St. Louis, MO).

2.1. Animals. Age matched male Sprague-Dawley (Harlan Laboratories, Indianapolis, IN) and ZDSD/Pco (provided by PreClinOmrics, Indianapolis, IN) rats were housed in a certified animal care facility and food (Purina 5008, Richmond, IN) and water were provided ad libitum. All institutional (approval ACURF no. 1202032) and NIH guidelines for use of animals were followed. At each stage of the studies all possible means were taken to avoid animal suffering and pain. At 16 weeks of age both Sprague-Dawley and ZDSD rats were placed on Purina diet 5SCA for 6 weeks (nutrient content for the Purina 5008 and 5SCA diets were protein 23.5 versus 10.5%, fat 6.5 versus 25.6%, fiber 6.0 versus 3.8%, and carbohydrates 49.4 versus 50.6%). During this time 9 of the 12 ZDSD rats spontaneously developed hyperglycemia with nonfasting blood glucose ranging from 387 to 558 mg/dL. The Sprague-Dawley rats maintained normal blood glucose levels during this period. Blood glucose levels were determined using glucose-oxidase reagent strips (Aviva Accu-Chek, Roche, Mannheim, Germany). After 6 weeks on the Purina 5SCA diet all rats were returned to the Purina 5008 diet and studied 12 weeks later. The three ZDSD rats that did not become hyperglycemic were excluded from the study.

2.2. Glucose Tolerance. Glucose tolerance was determined by injecting rats with a saline solution containing 2 g/kg glucose, i.p., after an overnight fast as previously described [16]. Rats were briefly anesthetized with isoflurane and the glucose solution was injected. Immediately prior to the glucose injection and at 15, 30, 45, 60, 90, 120, 180, and 240 min blood samples from the tip of the tail were taken to measure circulating glucose levels using glucose-oxidase reagent strips.

2.3. Thermal Nociceptive Response and Corneal Sensitivity. Thermal nociceptive response in the hindpaw was measured using the Hargreaves method as previously described [17]. Data was reported in sec. Corneal sensation was measured using a Cochet-Bonnet filament esthesiometer in unanaesthetized rats (Luneau Ophtalmologie, France) [18]. The testing began with the nylon filament extended to the maximal length (6 cm). The end of the nylon filament was touched to the cornea. If the rat blinked (positive response) the length of the filament was recorded. If the rat did not blink then the nylon filament was shortened by 0.5 cm and the test was repeated until a positive response was recorded. This process was repeated for each eye three times.

2.4. Motor and Sensory Nerve Conduction Velocity. On the day of terminal studies rats were weighed and anesthetized with Nembutal i.p. (50 mg/kg, i.p., Abbott Laboratories, North Chicago, IL). Motor and sensory nerve conduction velocities were determined as previously described using a noninvasive procedure in the sciatic-posterior tibial conducting system and digital nerve, respectively [17]. Motor and sensory nerve conduction velocities were reported in meters per second.

2.5. Corneal Innervation. Subbasal epithelial corneal nerves were imaged using the Rostock cornea module of the Heidelberg Retina Tomograph confocal microscope as previously described [18]. Briefly, the anesthetized rat was secured to a platform that allowed adjustment and positioning of the rat in three dimensions. A drop of GenTeal (lubricant eye gel) was applied onto the tip of the lens and advanced slowly forward until the gel contacted the cornea allowing optical but not physical contact between objective lens and corneal epithelium. Ten random high-quality images without overlap of the subbasal nerve plexus of the central cornea were acquired by finely focusing the objective lens to maximally resolve the nerve layer just under the corneal epithelium. For these studies a single parameter of corneal innervation was quantified [18]. Corneal nerve fiber length, defined as the total length of all nerve fibers and branches (in millimeters) present in the acquired image standardized for area of the image (in square millimeters), was determined for each image by tracing the length of each nerve in the image, summing the total length, and dividing by the image area [18]. The corneal fiber length for each animal was the mean value obtained from the ten acquired images and was expressed as mm/mm². Based on receiver operating characteristic (ROC) curve analysis, corneal nerve fiber length is the optimal parameter for diagnosing patients with diabetic neuropathy and has the lowest coefficient of variation [19, 20].

2.6. Intraepidermal Nerve Fiber Density and Langerhans Cells in Skin from the Hindpaw. As previously described, immunoreactive nerve fiber profiles innervating the skin from the hindpaw and number of Langerhans cells were determined using standard confocal microscopy [16–18]. Samples of skin of the right hindpaw were fixed, dehydrated, and embedded in paraffin. Three sections (7 μm) for each animal were collected and immunostained with anti-PGP9.5 antibody (rabbit anti-human, AbD Serotec, Morpho Sys US Inc., Raleigh, NC) overnight followed by treatment with secondary antibody Alexa Fluor 546 goat anti-rabbit. Immunostained nerve profiles and Langerhans cells were counted by two individual investigators that were masked to the sample identity. All immunoreactive profiles and cells were normalized to length [18].

2.7. Vascular Reactivity in Epineurial Arterioles. Video microscopy was used to investigate in vitro vasodilatory responsiveness of epineurial arterioles vascularizing the region of the sciatic nerve as previously described [21, 22]. The vessels used for these studies were generally oriented longitudinally in relation to the sciatic nerve; however, radially oriented vessels were also used on occasion. The
and calcitonin gene-related peptide ($10^{-11}$–$10^{-8}$ M). At the end of each dose response curve for acetylcholine or calcitonin gene-related peptide papaverine ($10^{-5}$ M) was added to determine maximal vasodilation.

### 3. Results and Discussion

Data in Table 1 show that at 8 weeks of age ZDSD rats weighed significantly more than Sprague-Dawley rats. However, at 34 weeks of age Sprague-Dawley rats weighed significantly more than the ZDSD rats. Prior to becoming hyperglycemic ZDSD rats are modestly obese compared to Sprague-Dawley rats but with the onset of hyperglycemia weight gain is reduced. At the end of the study period ZDSD rats had a significantly higher nonfasting blood glucose level and elevated hemoglobin
$\Delta_G$C value compared to Sprague-Dawley rats. Compared to Sprague-Dawley rats, at 34 weeks of age, ZDSD rats were hyperlipidemic as indicated by significantly increased serum free fatty acid, triglyceride, and cholesterol levels. Liver lipid levels were also significantly increased as indicated by significantly higher oil red staining of liver from ZDSD rats compared to Sprague-Dawley rats. Data in Table 1 also demonstrate that, in the sciatic nerve nitrotyrosine levels, a marker of oxidative stress is significantly increased.

Data in Figure 1 demonstrate that at 34 weeks of age, following a minimum of 12 weeks of hyperglycemia, ZDSD rats are severely glucose intolerant and insulin resistant as indicated by a very slow rate of glucose clearance compared to Sprague-Dawley rats.

A number of neural endpoints relating to diabetic neuropathy were examined in order to verify the extent of nerve damage that occurs in ZDSD rats. Determination of nerve conduction velocity is a standard endpoint used to study the effect of diabetes on nerve function. Data in Figure 2 demonstrate that both motor and sensory nerve conduction velocities are significantly slower in ZDSD rats compared to Sprague-Dawley rats at 34 weeks of age. More recently determining changes in small sensory nerve structure and function in the skin and cornea have been proposed as surrogate markers for diabetic neuropathy [19]. Data in Figure 3(a) demonstrate that ZDSD rats are thermal hypoalgesic as indicated by longer latency of withdrawal of their foot from a thermal stimulus compared to Sprague-Dawley rats. However, unlike other diabetic rodent models, the onset of chronic hyperglycemia did not cause a decrease in intraepidermal nerve fibers in the skin from the hindpaw (Figure 3(b)). In contrast, there was a significant decrease in the number of Langerhans cells (Figure 3(c)). These data suggest that impairment of thermal sensitivity in diabetes is not always associated with a decrease in intraepidermal nerve fiber density. This has previously been reported by others [25]. Beiswenger et al. reported that streptozotocin-diabetic mice developed thermal hypoalgesia prior to a measurable reduction in immunoreactive nerve fibers [25]. The decrease in Langerhans cells in ZDSD rats, after a minimum of 12 weeks of hyperglycemia, contrasts with what has been reported in streptozotocin-diabetic Sprague-Dawley rats [26]. Lauria et al. reported a reduction in intraepidermal nerve fiber density and a significantly higher density of Langerhans cells in the skin of the hindpaw [26]. In contrast, it has been reported that Langerhans cell density is significantly decreased in recently diagnosed type 2 diabetes patients [27]. In the latter study it was suggested that loss of Langerhans cells could promote a cutaneous immunogenic imbalance toward inflammation predisposing to polyneuropathy and foot ulcers [27]. Additional studies are needed to determine the role a change in the density of Langerhans cells may have in the development of diabetic neuropathy.

Data in Figure 4 demonstrate that nerves in the subepithelial layer of the cornea (a) are decreased and corneal sensitivity (b) is impaired in ZDSD rats compared to Sprague-Dawley rats. Even though chronic hyperglycemia does not appear to cause a decrease in intraepidermal nerve fiber density in the skin we did observe a significant decrease in the overall length of nerves in the subbasal epithelial layer of the cornea. This suggests that the pathophysiology controlling nerve fiber density in the skin and cornea may be different. Ziegler et al. recently reported in recently diagnosed type 2 diabetic patients that corneal confocal microscopy and skin biopsy both detected nerve fiber loss but largely in different patients [28], creating what they term as a patchy manifestation pattern of small fiber neuropathy in recently diagnosed type 2 diabetes [28].
The lack of a decrease in intraepidermal nerve fibers in the skin of the hindpaw of ZDSD rats along with thermal hypoalgesia was surprising. Decreased intraepidermal nerve fiber density has been widely reported to occur in rodent models of type 1 and type 2 diabetes including Zucker diabetic fatty rats and in humans with diabetes [29, 30]. We reported a correlation between decreased intraepidermal nerve fiber density and corneal nerve fiber density in type 2 diabetic rats [31]. It is not known whether the intraepidermal nerve fibers in ZDSD rats function normally. It is possible that the neuropeptide content of the intraepidermal nerve fibers in ZDSD rats is impaired. This could explain the decrease in thermal nociception in ZDSD rats even though the number of nerve fibers present in the skin is normal. Additional studies are needed to address this paradox.

We have previously demonstrated that diabetes causes a significant decrease in vascular relaxation of epineurial arterioles in type 1 and type 2 diabetic rat models [5–7, 17, 21, 22, 26, 32, 33]. We have theorized that reduced vascular reactivity of these blood vessels that supply circulation to the sciatic nerve could be a contributing factor to the development of diabetic neuropathy since vascular impairment precedes slowing of nerve conduction velocity [6, 21]. In these studies we demonstrate that vascular relaxation of epineurial arterioles from ZDSD rats to acetylcholine (Figure 5) and calcitonin gene-related peptide (Figure 6) is significantly impaired compared to Sprague-Dawley rats. Vascular relaxation to acetylcholine by small coronary and mesenteric arteries was also examined using previously described methodology and was found to be impaired (data not shown) [34, 35].

4. Conclusions

Chronic hyperglycemia in ZDSD rats causes vascular and neural dysfunction that is similar to what we have documented in other diabetic rat models and consistent with the development of diabetic neuropathy [5, 6, 16, 21, 22, 26]. The one exception is that chronic hyperglycemia in ZDSD rat
did not cause a decrease in intraepidermal nerve fibers in the skin as has been reported for other diabetic rat models but there was a decrease in Langerhans cells. Overall, the ZDSD rat is an easily maintained animal model for type 2 diabetes that spontaneously develops hyperglycemia with dietary manipulation. This is followed by the development of diabetic neuropathy including loss of nerves in the subbasal epithelial layer of the cornea and decrease in corneal function. Since determination of cornea nerve density and function are noninvasive and surrogate markers for diabetic neuropathy, the ZDSD rat with its functional leptin pathway may be a good model for preclinical testing of treatments for diabetic neuropathy [19].

Conflict of Interests

Richard G. Peterson is the developer of the ZDSD rat and could gain financially as a result of the marketing of this animal model. The other authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development (Merit Award BX001680), and Rehabilitation Research and Development (Merit Award: RX000889-01 and Center of Excellence: C9251-C). The content of this paper is new and is solely the responsibility of the authors and does not necessarily represent the official views of the granting agencies. The authors would like to acknowledge PreClinOmics Inc. (Indianapolis, IN), for providing the ZDSD rats.

References

[1] J. B. Clark, C. J. Palmer, and W. N. Shaw, “The diabetic Zucker fatty rat,” Proceedings of the Society for Experimental Biology and Medicine, vol. 173, no. 1, pp. 68–75, 1983.
[2] R. G. Peterson, W. N. Shaw, M. A. Neel, L. A. Little, and J. Eichberg, “Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus,” ILAR News, vol. 32, pp. 16–19, 1990.
[3] R. G. Peterson, M. A. Neel, L. A. Little, J. C. Kincaid, and J. Eichberg, “Neuropathic complications in the Zucker diabetic fatty rat (ZDF/ Drt-fa),” in Frontiers in Diabetes Research. Lessons From Animal Diabetes III, E. Shafrir, Ed., pp. 456–458, Smith-Gordon, London, UK, 1990.
[4] E. Shafrir, “Animal models of non-insulin-dependent diabetes,” Diabetes/Metabolism Reviews, vol. 8, no. 3, pp. 179–208, 1992.
[5] L. J. Coppey, J. S. Gellett, E. P. Davidson, J. A. Dunlap, and M. A. Yorek, “Changes in endoneurial blood flow, motor nerve conduction velocity and vascular relaxation of epineurial arterioles of the sciatic nerve in ZDF-obese diabetic rats,” Diabetes/Metabolism Research and Reviews, vol. 18, no. 1, pp. 49–56, 2002.
[6] C. L. Oltman, L. J. Coppey, J. S. Gellett, E. P. Davidson, D. D. Lund, and M. A. Yorek, “Progression of vascular and neural
dysfunction in sciatric nerves of Zucker diabetic fatty and Zucker rats,” *The American Journal of Physiology—Endocrinology and Metabolism*, vol. 289, no. 1, pp. E113–E122, 2005.

[7] C. L. Oltman, E. P. Davidson, L. J. Coppey et al., “Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse,” *Diabetes, Obesity and Metabolism*, vol. 10, no. 1, pp. 64–74, 2008.

[8] L. J. Coppey, J. S. Gellett, and M. A. Yorek, “Mediation of vascular relaxation in epineurial arterioles of the sciatric nerve: effect of diabetes in type 1 and type 2 diabetic rat models,” *Endothelium: Journal of Endothelial Cell Research*, vol. 10, no. 2, pp. 89–94, 2003.

[9] S. Reinwald, R. G. Peterson, M. R. Allen, and D. B. Burr, “Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models,” *American Journal of Physiology: Endocrinology and Metabolism*, vol. 296, no. 4, pp. E765–E774, 2009.

[10] J. E. Davis, J. Cain, W. J. Banz, and R. G. Peterson, “Age-related differences in response to high-fat feeding on adipose tissue and metabolic profile in ZDF rats,” *ISRN Obesity*, vol. 2013, Article ID 584547, 8 pages, 2013.

[11] J. Bełtowski, “Leptin and the regulation of endothelial function in physiological and pathological conditions,” *Clinical and Experimental Pharmacology and Physiology*, vol. 39, no. 2, pp. 168–178, 2012.

[12] J. Kaur, “A comprehensive review on metabolic syndrome,” *Cardiology Research and Practice*, vol. 2014, Article ID 943362, 21 pages, 2014.

[13] R. Ricci and F. Bevilacqua, “The potential role of leptin and adiponectin in obesity: a comparative review,” *Veterinary Journal*, vol. 191, no. 3, pp. 292–298, 2012.

[14] L. Duvnjak and M. Duvnjak, “The metabolic syndrome—an ongoing story,” *Journal of Physiology and Pharmacology*, vol. 60, pp. 19–24, 2009.

[15] W. Gade, J. Schmit, M. Collins, and J. Gade, “Beyond obesity: the diagnosis and pathophysiology of metabolic syndrome,” *Clinical Laboratory Science*, vol. 23, no. 1, pp. 51–65, 2010.

[16] E. P. Davidson, L. J. Coppey, N. A. Calcutt, C. L. Oltman, and M. A. Yorek, “Diabetes-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction,” *Diabetes/Metabolism Research and Reviews*, vol. 26, no. 4, pp. 306–318, 2010.

[17] E. P. Davidson, L. J. Coppey, A. Holmes, B. Dake, and M. A. Yorek, “Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications,” *European Journal of Pharmacology*, vol. 668, no. 3, pp. 497–506, 2011.

[18] E. P. Davidson, L. J. Coppey, A. Holmes, and M. A. Yorek, “Changes in corneal innervation and sensitivity and acetylcholine-mediated vascular relaxation of the posterior ciliary artery in a type 2 diabetic rat,” *Investigative Ophthalmology and Visual Science*, vol. 53, no. 3, pp. 1182–1187, 2012.

[19] C. Quattrini, M. Tavakoli, M. Jezierska et al., “Surrogate markers of small fiber damage in human diabetic neuropathy,” *Diabetes*, vol. 56, no. 8, pp. 2148–2154, 2007.

[20] M. Tavakoli, C. Quattrini, C. Abbott et al., “Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy,” *Diabetes Care*, vol. 33, no. 8, pp. 1792–1797, 2010.

[21] L. J. Coppey, E. P. Davidson, J. A. Dunlap, D. D. Lund, and M. A. Yorek, “Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatric nerve,” *Experimental Diabetes Research*, vol. 1, no. 2, pp. 131–143, 2000.

[22] K. Terata, L. J. Coppey, E. P. Davidson, J. A. Dunlap, D. D. Gutterman, and M. A. Yorek, “Acetylcholine-induced arteriolar dilation is reduced in streptozotocin-induced diabetic rats with motor nerve dysfunction,” *British Journal of Pharmacology*, vol. 128, no. 3, pp. 837–843, 1999.

[23] L. J. Coppey, A. Holmes, E. P. Davidson, and M. A. Yorek, “Partial replacement with menhaden oil improves peripheral neuropathy in high-fat-fed low-dose streptozotocin type 2 diabetic rat,” *Journal of Nutrition and Metabolism*, vol. 2012, Article ID 950517, 8 pages, 2012.

[24] S. Lupachyk, P. Watcho, H. Shevalye et al., “Na+/H+exchanger 1 inhibition reverses manifestation of peripheral diabetic neuropathy in type 1 diabetic rats,” *American Journal of Physiology—Endocrinology and Metabolism*, vol. 305, no. 3, pp. E396–E404, 2013.

[25] K. K. Beiswenger, N. A. Calcutt, and A. P. Mizisin, “Disso- ciation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice,” *Neuroscience Letters*, vol. 442, no. 3, pp. 267–272, 2008.

[26] G. Lauria, R. Lombardi, M. Borgna et al., “Intraepidermal nerve fiber density in rat foot pad: neuropathologic–neuropysiologic correlation,” *Journal of the Peripheral Nervous System*, vol. 10, no. 2, pp. 202–208, 2005.

[27] A. Strom, J. Brüggemann, I. Ziegler et al., “Pronounced reduction of cutaneous langerhans cell density in recently diagnosed type 2 diabetes,” *Diabetes*, vol. 63, no. 3, pp. 1148–1153, 2014.

[28] D. Ziegler, N. Papanas, A. Zhivotov et al., “Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes,” *Diabetes*, vol. 63, no. 7, pp. 2454–2463, 2014.

[29] K. K. Beiswenger, N. A. Calcutt, and A. P. Mizisin, “Epidermal nerve fiber quantification in the assessment of diabetic neuropathy,” *Acta Histochemica*, vol. 110, no. 5, pp. 351–362, 2008.

[30] V. Brussee, G. Guo, Y. Dong et al., “Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model,” *Diabetes*, vol. 57, no. 6, pp. 1664–1673, 2008.

[31] E. P. Davidson, L. J. Coppey, R. H. Kardon, and M. A. Yorek, “Differences and similarities in development of corneal nerve damage and peripheral neuropathy and in diet- induced obesity and type 2 diabetic rats,” *Investigative Ophthalmology and Visual Science*, vol. 55, no. 3, pp. 1222–1230, 2014.

[32] M. A. Yorek, L. J. Coppey, I. S. Gellett, and E. P. Davidson, “Sensory nerve innervation of epineurial arterioles of the sciatric nerve containing calcitonin gene-related peptide: effect of streptozotocin-induced diabetes,” *Experimental Diabetes Research*, vol. 5, no. 3, pp. 187–193, 2004.

[33] E. P. Davidson, L. J. Coppey, T. L. Kleinschmidt, C. L. Oltman, and M. A. Yorek, “Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688,” *Experimental Diabetes Research*, vol. 2009, Article ID 912327, 8 pages, 2009.

[34] C. L. Oltman, L. L. Richou, E. P. Davidson, L. J. Coppey, D. D. Lund, and M. A. Yorek, “Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats,” *The American Journal of Physiology—Heart and Circulatory Physiology*, vol. 291, no. 4, pp. H1780–H1787, 2006.

[35] C. L. Oltman, T. L. Kleinschmidt, E. P. Davidson, L. J. Coppey, D. D. Lund, and M. A. Yorek, “Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes,” *Vascular Pharmacology*, vol. 48, no. 1, pp. 47–53, 2008.